Clinical Trials Logo

Vaginosis, Bacterial clinical trials

View clinical trials related to Vaginosis, Bacterial.

Filter by:

NCT ID: NCT01072136 Terminated - Cervicitis Clinical Trials

Empiric Therapy of Mucopurulent Cervicitis (MPC)

Start date: March 2010
Phase: Phase 3
Study type: Interventional

Mucopurulent cervicitis (MPC) is a syndrome with associated symptoms including mucopurulent discharge (mucus and pus) from the cervix and other signs of inflammation such as easily induced cervical bleeding. The purpose of this study is to evaluate the effectiveness of no treatment versus empiric treatment with a single dose of cefixime and azithromycin for cure of MPC. Empiric treatment is the initiation of treatment prior to a firm diagnosis. Study participants will include 772 women ages 18 and older in good health with MPC. Women will be randomly assigned to 1 of 2 possible study groups: Group 1 will receive a single dose of cefixime and azithromycin antibiotics and Group 2 will receive placebo (inactive substance). Study procedures will include pelvic examination with a cervical swab sample. Participants will be involved in study related procedures for approximately 2 months, which includes 3 study visits.

NCT ID: NCT00741845 Terminated - Bacterial Vaginosis Clinical Trials

Prevention of Persistence of Bacterial Vaginosis

Start date: June 2008
Phase: Phase 3
Study type: Interventional

This purpose of this study will be to conduct a double-blind, randomized, controlled clinical trial to determine the association between intravaginal high dose metronidazole (750mg), intravaginal high dose metronidazole combined with an antifungal agent(750mg metronidazole + 200mg miconazole) and low dose (37.5mg) intravaginal metronidazole, with the rate of persistent bacterial vaginosis.

NCT ID: NCT00303082 Terminated - Sepsis Clinical Trials

Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The trial intends to evaluate the efficacy of specially designed probiotics to prevent premature birth and related neonatal morbidity associated to intra-uterine infection. The tested probiotics are efficacious to decrease the prevalence of bacterial vaginosis. The study hypothesis is that the early administration of those probiotics to pregnant women with bacterial vaginosis can prevent premature birth through antibiotic activity and modulation of the immune response to infection.